




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 209/42, A61K 31/40	A1	(11) International Publication Number: WO 95/19966 (43) International Publication Date: 27 July 1995 (27.07.95)
<p>(21) International Application Number: PCT/EP95/00193</p> <p>(22) International Filing Date: 19 January 1995 (19.01.95)</p> <p>(30) Priority Data: FI94A000009 19 January 1994 (19.01.94) IT</p> <p>(71) Applicants (for all designated States except US): A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. [IT/IT]; Via Sette Santi, 3, I-50131 Florence (IT). MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. [IT/IT]; Via Porpora, 22/24, I-50144 Florence (IT).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): SISTO, Alessandro [IT/IT]; Via Proba Petronia, 43, I-00136 Rome (IT). POTIER, Edoardo [IT/IT]; Viale dei Salesiani, 82, I-00175 Rome (IT). MANZINI, Stefano [IT/IT]; Via della Mattonaia, 25, I-50121 Florence (IT). FINCHAM, Christopher [GB/IT]; Via Don Luigi Sturzo, 28 Km 15, I-00040 Pomezia (IT). LOMBARDI, Paolo [IT/IT]; 16a Strada, 22, I-20020 Cesate (IT). ARCAMONE, Federico [IT/IT]; Via 4 Novembre, 26, I-20014 Nerviano (IT).</p> <p>(74) Agent: GERVASI, Gemma; Notarbartolo & Gervasi S.r.l., Viale Bianca Maria, 33, I-20122 Milano (IT).</p>		<p>(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: TACHYKININS ANTAGONISTS</p> <p>(57) Abstract</p> <p>The present invention refers to tachykinins antagonists of general formula (I), their preparation and pharmaceutical compositions containing them.</p> <div style="text-align: right;">  <p>(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Tachykinins antagonists.

Field of the invention

The present invention refers to tachykinins antagonists of general
5 formula (I)




wherein:

Y is chosen in the group consisting of aryl-, aryl-alkyl-, alkyl-aryl-
radical containing from 7 to 12 carbon atoms possibly substituted in the
ring with at least one atom chosen in the group consisting of N, S and O
10 and possibly substituted on the ring with one or more substituents
independently chosen from halogen, alkyl-radical containing from 1 to 6
carbon atoms possibly substituted with no more than three fluorine atoms
(for example trifluoromethyl group), oxyalkyl-radical containing from 1
to 6 carbon atoms, possibly substituted with no more than three fluorine
15 atoms (for example trifluoromethoxyl group), -NH₂, -NHR₁₀, -OR₁₀, -
N(R₁₀)₂, -CONHR₁₀, -COR₁₀, -COOR₁₀, -R₁₀COOR₁₁, -OR₁₀COOR₁₁, -R₁₀COR₁₁,
-CONHR₁₀, -R₁₀CONHR₁₁, -NHCOR₁₀, nitro-radicals wherein R₁₀ and R₁₁ are
hydrogen or an alkyl-radical, linear or branched, containing from 1 to 6
carbon atoms.

- 2 -

or Y is a radical of formula:



- wherein D = O, S, CH₂ and N-R₄ wherein R₄ is chosen in the group constituted by hydrogen, an alkyl-radical, linear or branched, containing from 1 to 6 carbon atoms, an acyl-radical R₉-CO, wherein R₉ is hydrogen or an alkyl-chain containing from 1 to 3 carbon atoms, and wherein E = CH
- 5 or N, anyone of which can bear suitable substituents;
- X₁ and X₂, same or different from each other, are chosen in the group consisting of -CONR₈, -NR₈CO-, -CH₂NR₈-, -SO₂NR₈-, wherein R₈ is chosen in the group consisting of hydrogen or an alkyl-chain, linear or modified, containing from 1 to 6 carbon atoms;
- 10 X₃ is chosen in the group consisting of -CONR₇, -NR₇CO-, -CH₂NR₇-, -SO₂NR₇-, -CN₄-, wherein -CN₄- is a tetrazoline ring and R₇ is chosen in the group consisting of alkyl-, aryl-, aryl-alkyl- or alkyl-aryl-radical with no more than 15 carbon atoms possibly substituted in the ring with at least an atom chosen in the group consisting of N, S and O, possibly
- 15 substituted on the ring with one or more substituents independently from each other chosen from halogen, alkyl-radical containing from 1 to 6 carbon atoms, possibly substituted with no more than three fluorine atoms (for example trifluoromethyl group), oxyalkyl-radical containing from 1 to 6 carbon atoms, possibly substituted with no more than three
- 20 fluorine atoms (for example trifluoromethoxyl group), -NH₂, -NHR₁₀, -OR₁₀, -N(R₁₀)₂, -CONHR₁₀, -COR₁₀, -COOR₁₀, -R₁₀COOR₁₁, -OR₁₀COOR₁₁, -

- 3 -

$R_{10}COR_{11}$, $-CONHR_{10}$, $-R_{10}CONHR_{11}$, $-NHCOR_{10}$, nitro-radicals, wherein R_{10} and R_{11} are hydrogen or an alkyl-radical, linear or branched, containing from 1 to 6 carbon atoms;

R_1 , R_2 and R_3 independently from each other are hydrogen, halogen, OR_{12} wherein R_{12} is chosen in the group consisting of hydrogen,

$-CH_2O(CH_2)_2OCH_3$ or $-CH_2O(CH_2)_2OCH_2CH_3$, or are linked two by two to form an epoxide; A and B can be N, S, O or CH; n is a number from 0 to 2;

R_5 and R_6 are chosen, independently from each other, in the group consisting of hydrogen, alkyl-, aryl-, aryl-alkyl or alkyl-aryl-radical containing no more than 15 carbon atoms, possibly substituted in the ring with at least an atom chosen in the group of N, S and O, possibly substituted on the ring with one or more substituents chosen independently from each other from halogen, alkyl-radical containing from 1 to 6 carbon atoms, possibly substituted with no more than three fluorine atoms (for example trifluoromethyl group), oxyalkyl-radical containing from 1 to 6 carbon atoms, possibly substituted with no more than three fluorine atoms (for example trifluoromethoxyl group), an $-NH_2$, $-NHR_{11}$, $-OR_{10}$, $-N(R_{10})_2$, $-CONHR_{10}$, $-COR_{10}$, $-COOR_{10}$, $-R_{10}COOR_{11}$, $-OR_{10}COOR_{11}$, $-R_{10}COR_{11}$, $-CONHR_{10}$, $-R_{10}CONHR_{11}$, $-NHCOR_{10}$, nitro-radicals, wherein R_{10} and R_{11} are hydrogen or an alkyl-radical, linear or branched, containing from 1 to 6 carbon atoms.

The invention refers also to the process for their preparation and to pharmaceutical compositions containing them.

State of the art

Tachykinins are a family of at least three peptides, known as Substance P, Neurokinin A (NKA) and Neurokinin B (NKB).

- 4 -

The research in the field of tachykinins antagonists, initially based principally on single or multiple substitutions of the amino acids present in the sequence of peptidic-agonists of Substance P and of the other tachykinins, brought to the discovery of nonapeptides containing
5 one or more units of D-triptophane (Regoli et al. Pharmacol. 28, 301 (1984)). On the other hand the problems connected with the use as pharmaceuticals products of peptides presenting an high molecular weight (multiplicity of enzymatic hydrolytic attack sites, poor bioavailability, rapid excretion by the liver and kidneys) spurred to search for the
10 smallest peptide fragment still capable of exerting an antagonistic action. These studies brought to the singling out of tri- and di-peptides, suitably substituted, antagonist of Substance P (EP-333 174 and EP- 394 989).

Recently non-peptidic antagonists were reported which do not present
15 the drawbacks of the metabolic instability of peptides (Italian Application MI 92 A 002779):

The compounds of the present invention show antagonism against Substance P, Neurokinin A and Neurokinin B.

Therefore, the above said compounds can be used as pharmaceutical
20 compounds in the treatment and prevention of those disorders wherein the tachykinins Substance P, Neurokinin A and Neurokinin B play a role as neuromodulators.

The compounds of formula (I) are useful for the treatment of disorders wherein the tachykinins play a pathogenic role in particular in the
25 treatment of arthritis, asthma, inflammations, tumoral growth, Huntington's disease, neuritis, neuralgia, migraine, hypertension,

- 5 -


incontinence of urine, urticaria, carcinoid syndrome symptoms, influenza and cold, disorders related to the immuno system.

By way of example, reference can be made to pathologies of the respiratory system as asthma, allergic rhinitis; ophthalmic system as conjunctivitis;
5 cutaneous system as allergic dermatitis, dermatitis by contact, psoriasis; intestinal system as ulcerative colitis and Chron's disease.

Detailed description of the invention


It was surprisingly found, and this is a fundamental characteristic of the present invention, that non-peptidic compounds of general formula
10 (I), as previously defined, show better inhibition of the tachykinins bond to the NK1 receptor and high metabolic stability.

In particular, a preferred group of compounds of the present invention comprises the compounds of formula (I) wherein:



wherein $X_1 = -CONH-$, $X_2 = -CONH-$ and $X_3 = -CONCH_3-$ and wherein R_1 , R_2 ,
15 R_3 , R_4 , R_5 , R_6 , R_7 , R_9 , R_{10} , R_{11} , A and B are as above defined.

Particularly preferred are the compounds of formula (I) wherein:



- 6 -

wherein $X_1 = -\text{CONH}-$, $X_2 = -\text{CONH}-$ and $X_3 = -\text{CONCH}_3-$, $R_5 = 2$ -methylnaphthyl and $R_6 = \text{benzyl}$.

In the present invention the alkyl-radical is preferably chosen in the group of: methyl, ethyl, propyl, butyl and pentyl; the alkenyl-radical is
5 chosen between propenyl and butenyl; the aryl-, alkyl-aryl and aryl-alkyl-radical preferably presents an alkyl-radical as above defined while the aryl moiety is preferably pyridine, pyrrole, benzofuran, biphenyl, benzene, indole, naphthalene, tetrahydroquinoline, imidazole, tetrahydroindoline, quinoline, thienyl, furan, thiofene, indan, possibly
10 substituted as above defined; cycloalkyl-radical possibly substituted with at least an atom chosen in the group of N, S and O is preferably selected in the group of cyclohexane, cyclopentane, cyclooctane, piperidine, morpholine, piperazine and pyrazine.

As oxyalkyl-radical is preferred a: methyloxy, ethyloxy, propyloxy,
15 trifluoromethyloxy, while as alkyl radicals methyl and trifluoromethyl are preferred.


Halogen, as used herein, means fluorine, chlorine, bromine and iodine and the groups substituted with no more than three fluorine atoms are preferably tri-substituted.

20 In view of the asymmetry centres of formula (I), the invention refers to the various diastereoisomers of said formula, in particular the substituent R_5 is preferably in the S-configuration.


The compounds of general formula (I), as above defined, are prepared according to the following reaction paths and description, wherein, if
25 not otherwise indicated, R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{12} , A, B, X_1 , X_2 , X_3 are as above defined.

- 7 -

a) By condensation, in the presence of a suitable condensing agent, of the intermediate of formula (II), wherein X_4 is COOH or NH_2 :



with the intermediate of formula (III), wherein X_5 is NH_2 when X_4 is COOH, while when X_4 is NH_2 , X_5 is COOH:



5 The intermediate of general formula (II) is prepared for example according to Scheme 1.

Such Scheme shows the preparation of an intermediate of general formula (IIa) wherein X_1 is $-CH_2-N(Prot_2)-$, by reductive amination of a compound of general formula (V), as above defined, and an aldehyde of general
 10 formula $Y-CHO$ with sodium cyanoborohydride or sodium borohydride to give the corresponding intermediate of general formula (VI); this reaction is preferably carried out in acetic acid or alcohol at room temperature, maintaining the pH slightly acid, preferably at pH 4.5. The intermediate (VI) is substituted, giving the intermediate (VII), in order to protect
 15 the amino group, and the ester is finally splitted by basic hydrolysis:

- 8 -

preferably the group introduced is the tert-butyloxycarbonyl-group, and such reaction was carried out with ditert-butylcarbonate in aprotic polar solvents, preferably tetrahydrofuran, at room temperature.


Such intermediate of general formula (III) is prepared, for example,
5 according to Scheme 2.

Scheme 2 describes the preparation of an intermediate of general formula IIIa, wherein $X_3 = NR_7CO$ and R_6 , R_5 , R_7 are as above defined, HX is an acid chosen in the group: acetic acid, chloridric acid, sulfuric acid, trifluoroacetic acid and the configuration of the carbon atom to which
10 group R_5 is linked is preferably S. Such intermediate is prepared by reaction between the D-amino acid derivative of general formula (VIII), commercially available or prepared as described in the examples, or by any other synthetic way obvious for the man skilled in the art, and the alkyl-halogenide of general formula R_7-Hal , wherein Hal is chosen in the
15 group of chlorine, iodine or bromine and R_7 is as above described, in the presence of a base, chosen in the group of alkaline- or earth-alkaline-hydrides in an inert, aprotic, polar solvent, for example tetrahydrofuran or dioxane. In particular the reaction is performed at 0°C in tetrahydrofuran using as base sodium-hydride and as alkylating agent
20 methyl iodide. The following reaction with the ammonium salt of hydroxybenzotriazole, carried out in the presence of a suitable condensing agent, gives the corresponding amide (X); the latter by reaction with bis(trifluoroacetoxy)iodobenzene produces the gem-diamine derivative (IIIa); such reaction is carried out at room temperature in a
25 water/acetonitrile mixture.

Another synthesis-path, known by the man skilled in the art, is the

- 9 -

sequential condensation on the intermediate of general formula (III), as above defined, of the two residues of general formula (XI) and (XII)



After the condensation of the first fragment (XI), the elimination of the protecting group Prot_3 , allows the liberation of the amino-group and the subsequent condensation of fragment (XII), wherein Prot_3 is preferably the tert-butyloxycarbonyl-group and the elimination step is an acid lysis, preferably carried out with a saturated solution of hydrochloric acid in organic solvents as ethyle acetate, ethyl ether, dioxane.

b) The reaction by-products are eliminated by evaporating the reaction solvent and treating the residue or a solution thereof in a suitable organic solvent with slightly acid or slightly basic solutions.

c) The crude product obtained from step (b) is purified by chromatography or by crystallization.

The above described condensations can be performed according to the information known in literature for peptide-synthesis.

Excellent product yield and purity, were obtained using, as condensing agent, the benzotriazolyloxytripyrrolidine phosphonium hexafluorophosphate (PyBop). In particular the reaction was carried out

- 10 -

with addition of slight excess of PyBop to a carboxylic component solution, maintained at low temperature, followed by addition of the hydrochloride aminic component and a quantity of tertiary amine of three equivalents in respect to the condensing agent.

- 5 An alternative procedure envisages the use, as condensing agent, of 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide (WSC.HCl).

For the condensation reaction, which can be preferably carried out at room temperature, the usual polar, aprotic organic solvents chosen in the group of dimethylformamide, dioxane, tetrahydrofuran, methylene chloride,

- 10 dichloroethane, chloroform are used.

Another object of the present invention are therefore the processes for the preparation of the intermediates of formula (II) and (III) and such intermediates obtained through the above said processes.

- The compounds of the present invention can exist in different isomeric
15 configurations. In fact, while the configuration of the carbon atom bound to substituent R_5 is univocally predetermined by the amino acid chosen as starting product, the other starting compounds can be a mixture of enantiomers difficult to separate. It follows that the present compounds can be obtained as diastereoisomers mixtures. Said mixtures can be easily
20 resolved by chromatography. In any case compounds of formula (I) can be used both in optically active form and in the form of isomeric mixtures. For their therapeutical use the compounds according to the present invention can be administered parenterally, intranasally, orally or sublingually. The formulations containing the new compounds can be
25 prepared, according to known techniques, combining the active principle with an inert carrier and possibly with the conventional additives

- 11 -

suitably chosen. In view of the oral or sublingual use the present compounds can be administered as tablets, pellets, drops, elixir, ecc., prepared with the conventional carriers/excipients as starch, sugars, water, alcohol ecc. and possibly comprising aromatizing agents, stabilizers, preservatives, lubricants ecc. For parenteral or intranasal administration the preferred carrier is sterilized water for injection. Additives can be added according to the known art.

The therapeutically effective daily dosage can vary according to the subject under treatment (weight, age, disease gravity) and to the administration route. Generally it can be said that the present compounds are active when subministered in a daily dosage of 0.005 to 10 mg/Kg. The pharmaceutical compositions according to the present invention will contain the active product in a suitable quantity in order to allow a correct daily dosage in the above said range, normally by 1 - 3 administrations per day.

The following example is given for better illustrating the invention.

EXAMPLE

$N^Q[N-(1(H)\text{indol-3-yl-carbonyl})-1\text{-amino-cyclohexan-carbonyl}]-L-2\text{-naphthylalanine-}N\text{-methyl-}N\text{-benzylamide [I3c-1-Ac}^6\text{c-L-2NaI-NMeBz]}$

For the sake of simplicity the following abbreviations were also used: $1\text{-Ac}^6\text{c}$, for the 1-amino-cyclohexancarboxylic-acid; I3c, for the 1(H)indol-3-yl-carbonyl-residue; the indications normally used for the peptide synthesis.

1a) To an amino-cyclohexanecarboxylic-acid (1.4 g) in 14 ml of NaOH 2N, cooled at 0°C under vigorous stirring in nitrogen current, a solution of di-tert-butyl-dicarbonate (9.1 g) in 14 ml of isopropanole was added. The

- 12 -

solution was left under stirring at room temperature for 16 hours.

The isopropanole was evaporated in vacuo and the aqueous solution was extracted with ethyl ether (3 x 50 ml). The aqueous phase was acidified to pH 3 with HCl 1N and extracted with ethyle acetate (3 x 50 ml). The
5 organic solution was washed with a solution saturate in NaCl (3 x 50 ml), dried on Na₂SO₄ and the solvent was eliminated obtaining 309 mg of N^α(tert-butyloxy-carbonyl)-1-aminocyclohexanecarboxylic acid (Boc-1-Ac⁶c-OH) (yield 47%). TLC [chloroform/methanole 9:1 v/v (CM)] = 0.36.

1b) to a solution of N^α(tert-butyloxy-carbonyl)-L-2-naphthylalanine (500
10 mg) in 7 ml of anhydrous DCM, at 0°C under vigorous stirring in nitrogen current, N,N-methylbenzylamine (0.25 ml), N-hydroxybenzotriazolyl-tripyrrolidine phosphonium hexafluorophosphate (PyBop) (0.998 g) and finally, slowly, DiPEA (0.63 ml) are added. The solution is left under stirring at 0°C for 30' and at room temperature for 16 hours. The
15 solvent is eliminated by evaporation in vacuo and the residue is collected with EtOAc (50 ml). The organic solution is extracted with an aqueous solution of NaHCO₃ (3 x 50 ml), therefater with an aqueous solution saturated in NaCl (3 x 50 ml), with an aqueous solution of HCl 0.1 N (3 x 50 ml) and finally again with an aqueous solution saturated in
20 NaCl (3 x 50 ml). The organic phase is dried on Na₂SO₄ and the solvent is eliminated giving a slightly yellow oil which is purified by chromatography on silica using as eluent hexane/ethyle acetate 70:30 (v/v) giving 478 mg of N^α(tert-butyloxycarbonyl)-L-2-naphthylalanine-N-methyl-N-benzyl amide (yield 71%).

25 TLC [chloroform/methyl alcohol 95:5 v/v] = 0.85.

for the HPLC a Phase Sep. Spherisorb ODS-2^R 5μ 46 x 250 mm was used and

- 13 -

as eluents:

A = 0.1 trifluoroacetic acid in acetonitrile

B = 0.1 trifluoroacetic acid in water

linear gradient of 20% A to 80% A over 25 min; isocratic conditions at
5 80% of A for 10 min, flow 1 ml/min; determination by UV at 230 nm.

Analytical HPLC shows a single peak at $T_R = 28.55$ min.

1c) A suspension of the product obtained in the previous step (1b) (0.474
g) in 9 ml of a solution of EtOAc saturated of HCl (about 2N) is left
under stirring at room temperature for 30 min. The solvent is eliminated
10 under a slight nitrogen current and the residue is repeatedly suspended
in ethyl ether (4 x 30 ml), the solvent is eliminated giving 0.400 mg
of L-2-naphthylalanine-N-methyl-N-benzyl amide hydrochloride (yield 99%).
TLC [chloroform/methyl alcohol 95:5 v/v]: $R_f = 0.15$.

Analytical HPLC in the same conditions given for step (1b) shows a single
15 peak, large, at $T_R = 24.44$ min.

1d) To a solution of the compound of step (1a) (0.170 g) in DCM (2 ml)
and DMF (0.2 ml), at 0°C under vigorous stirring in nitrogen current,
0.11 g of HOBT and 0.16 g of WSC.HCl are added. The solution is left
under stirring at 0°C for 30' and thereafter 0.25 g of the compound
20 obtained in step (1c) and 0.28 ml of diisopropylethylamine are added.
After 16 hours stirring at room temperature, the solvent was eliminated
by evaporation in vacuo and recollected with ethyl acetate. The organic
solution is extracted with an aqueous solution of NaHCO_3 at 5% (3 x 50
ml), thereafter with an aqueous solution saturated in NaCl (3 x 50 ml),
25 then with an aqueous solution of HCl 0.1 N (3 x 50 ml) and finally again
with an aqueous solution saturated in NaCl (3 x 50 ml). The organic phase

- 14 -

is dried on Na_2SO_4 and the solvent is eliminated. The residue is solubilized in 20 ml of an ethyl acetate solution saturated with hydrochloric acid (about 2N). After 1 hour stirring at room temperature, the solvent is evaporated under nitrogen current, the residue is
5 recollected twice with absolute etanole and the solvent is eliminated. The compound is cristallized from carbon tetrachloride giving 320 mg of N^{α} (1-aminocyclohexylcarbonyl)-L-2-naphthylalanine-N-metil-N-benzyl-amine hydrochloride (yield 95%).

TLC [Chloroform/methyl alcohol/acetic acid 85:10:5 v/v]: $R_f = 0.43$.

10 Analytical HPLC in the same conditions as in step (1b) shows a single peak, large, at $T_R = 28.16$ min.

1e) A suspension of 3-indolyl-carboxylic acid (0.125 g) in 1.6 ml of a 1 M solution of oxalyl chloride in benzene, cooled at 0°C , is kept under stirring in nitrogen current for 1 hour. After addition of two drops of
15 DMF, the solution, now clear and slightly yellow, is left under stirring at room temperature for another hour. The solvent was eliminated by evaporation under reduced pressure and the residue was recollected with 1 ml of DCM, the resulting solution was added to a solution of the compound obtained in step (1d) (40 mg) and diisopropylethylamine (0.23 ml) in 0.5
20 ml DCM. The solution was left under stirring at room temperature for 24 hours. After elimination of the solvent under reduced pression, the residue was recollected in ethyl acetate (5 ml) and extracted with an aqueous solution of 5% NaHCO_3 (3 x 50 ml), then with an aqueous solution saturated in NaCl (3 x 50 ml), with an aqueous solution of HCl 0.1 N (3 x
25 50 ml) and finally with an aqueous solution saturated of NaCl (3 x 50 ml). The organic phase is dried over Na_2SO_4 and the solvent is

- 15 -

eliminated. The product is isolated by reversed-phase chromatography on a Hibar Merck column filled with Lichrosorb RP-18^R (7 m), eluting with isocratic at 65% of A (eluent of step 1b), flow 8 ml/min. The fractions corresponding to the product peak were pooled, concentrated to small
5 volume under reduced pressure and repeatedly free-dried giving 9 mg of N^α[N-(1(H)indol-3-yl-carbonyl)-1-amino-cyclohexanecarbonyl]-L-2-naphthylalanine-N-methyl-N-benzyl amide.

Analytical HPLC, in the same conditions described for step (1b) shows a single peak at T_R = 27.71 min.

10 Operating as above described the following compounds were obtained:

- i) 1-N-[N(1(H)indol-3-yl-carbonyl)-1-amino-cyclohexanecarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]amino-2-phenylethane
- ii) 1-[N(1(H)indol-3-yl-carbonyl)-1-amino-cyclohexanecarbonyl]-amino-1[N-(2-phenylacetyl)amino]-2-(2-naphthyl)ethane
- 15 iii) 1-N-[N(benzoyl)-1-amino-cyclohexanecarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]amino-2(2-naphthyl)ethane
- iv) 1-N-[N(4-methyl-benzoyl)-1-amino-cyclohexanecarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]amino-2(2-naphthyl)ethane
- v) 1-N-[N(4-methoxy-benzoyl)-1-amino-cyclohexanecarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]amino-2(2-naphthyl)ethane
- 20 vi) 1-N-[N(4-chloro-benzoyl)-1-amino-cyclohexanecarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]amino-2(2-naphthyl)ethane
- vii) 1-N-[N(3,4-chloro-benzoyl)-1-amino-cyclohexanecarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]amino-2(2-naphthyl)ethane
- 25 viii) 1-N-[N(1(methyl)indol-3-yl-carbonyl)-1-amino-cyclohexanecarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]amino-2(2-naphthyl)ethane

- 16 -

- ix) 1-N-[N(1(H)indol-3-yl-methyl)-1-amino-cyclohexancarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]amino-2(2-naphthyl)ethane
- x) 1-N-[N(1(methyl)indol-3-yl-carbonyl)-N-methyl-1-amino-cyclohexancarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]amino-2(2-naphthyl)ethane
- 5 xi) 1-N-[N(1(H)indol-3-yl-carbonyl)-1-amino-cyclohexancarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]amino-2(p-methoxy)phenylethane
- xii) N-[N(1(methyl)indol-3-yl-carbonyl)-N-methyl-1-amino-cyclohexancarbonyl]-2 naphthylalanine-N-methyl-N-benzylamide
- 10 xiii) N-[N(1(methyl)indol-3-yl-carbonyl)-N-methyl-1-amino-cyclohexancarbonyl]-2 naphthylalanine-N-methyl-N-benzylamide
- xiv) 1-N-[N(1(H)indol-3-yl-carbonyl)-1-amino-cis-4-hydroxy-cyclohexancarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]-amino-2-phenylethane
- 15 xv) 1-[N-(1(H)indol-3-yl-carbonyl)-1-amino-trans-4-hydroxy-cyclohexancarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]-amino-2-(2-naphthyl)ethane
- xvi) 1-N-[N(1(H)indol-3-yl-carbonyl)-1-amino-cis-4-methoxyethoxymethoxyl-cyclohexancarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]-amino-2-phenylethane
- 20 xvii) 1-[N(1(H)indol-3-yl-carbonyl)-1-amino-trans-4-methoxyethoxymethoxyl-cyclohexancarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]-2(2-naphthyl)ethane
- xviii) N-[N(1(H)indol-3-yl-carbonyl)-1-amino-cis-4-hydroxy-cyclohexancarbonyl]-2-naphthylalanine-N-methyl-N-benzylamide
- 25 xix) N-[N(1(H)indol-3-yl-carbonyl)-1-amino-trans-4-hydroxy-

- 17 -

- cyclohexancarbonyl]-2-naphthylalanine-N-methyl-N-benzylamide
- xx) N-[N(1(H)indol-3-yl-carbonyl)-1-amino-cis-4-methoxyethoxymethoxyl-cyclohexancarbonyl]-phenylalanine-N-methyl-N-benzylamide
- xxi) N-[N(1(H)indol-3-yl-carbonyl)-1-amino-trans-4-methoxyethoxymethoxyl-cyclohexancarbonyl]-phenylalanine-N-methyl-N-benzylamide
- 5 xxii) 1-[N(1(H)indol-3-yl-carbonyl)-1-amino-4-dimethoxycyclohexancarbonyl]-amino-1-[N(methyl)-N(2-phenylacetyl)]-amino-2-(2-naphthyl)ethane
- 10 xxiii) N-[N(1(H)indol-3-yl-carbonyl)-1-amino-4-dimethoxycyclohexancarbonyl]-2-naphthylalanine-N-methyl-N-benzylamide
- xxiv) 1-[N(1(H)indol-3-yl-carbonyl)-1-amino-4-di(methoxyethoxyethoxy)-cyclohexancarbonyl]-amino-1-[N(methyl)-N(2-phenylacetyl)]-amino-2-(2-naphthyl)ethane
- 15 xxv) N-[N(1(H)indol-3-yl-carbonyl)-1-amino-4-di(methoxyethoxymethoxy)-cyclohexancarbonyl]-2-naphthylalanine-N-methyl-N-benzylamide
- xxvi) 1-[N(1(H)indol-3-yl-carbonyl)-4-amino-tetrahydropyranyl-4-carbonyl]-amino-1[N(methyl)-N(2-phenylacetyl)]-amino-2-(2-naphthyl)ethane
- xxvii) N-[N(1(H)indol-3-yl-carbonyl)-4-amino-tetrahydropyranyl-4-carbonyl]-2-naphthylalanine-N-methyl-N-benzylamide
- 20 xxviii) 1-[N(1(H)indol-3-yl-carbonyl)-4-amino-piperidin-4-carbonyl]-amino-1[N(methyl)-N(2-phenylacetyl)]-amino-2-(2-naphthyl)ethane
- xxix) N-[N(1(H)indol-3-yl-carbonyl)-4-amino-piperidin-4-carbonyl]-2-naphthylalanine-N-methyl-N-benzylamide
- 25 xxx) 1-[N(1(H)indol-3-yl-carbonyl)-4-amino-1-dimethyl-piperidin-4-carbonyl]-amino-1-[N(methyl)-N(2-phenylacetyl)]-amino-2-(2-

- 18 -

naphthyl)ethane

xxxi) N-[N(1(H)indol-3-yl-carbonyl)-4-amino-1-dimethylpiperidin-4-carbonyl]-2-naphthylalanine-N-methyl-N-benzylamide

The evaluation of the antagonist activity of NK1 receptors was performed
5 with binding and functional tests.

[³H]SP binding assay in IM9 Cell Line.

The assay was carried out on intact cells as described by Payan et al. (1984). The cells were washed with buffer A at pH 7.5 containing (in mM) Tris-HCl 50, NaCl 150 and 0.02% BSA, thereafter were resuspended in a
10 dosage buffer (buffer A added with protease inhibitors), concentration : $\times 10^7$ cells/ml. The cells were incubated with [³H]SP in a final volume of 0.5 ml for 60' at room temperature. The non-specific binding was calculated in the presence of 10 mM of non-radioactive SP. The dosage mixture was poured in test tubes for microcentrifugation which were
15 preadsorbed in a solution of BSA 0.5% for at least 3 hours. [³H]SP, free and binded, was separated by cell sedimentation with a microcentrifuge (6 min at 12000 g); the supernatant was removed by aspiration. For competitive tests, the cells IM9 were incubated in triplicate with 0.3 nM of [³H]SP (average value of Kd calculated in saturation experiments) and
20 the competitive ligands were added at six different concentrations (with dilution 1:10 in the dosage buffer) in order to obtain a complete competition curve. The affinity was measured as pKi.

Measurement of pA2 in isolated guinea pig ileum

Male guinea pigs weighing 300-350 g were sacrificed. A ring of ileum
25 (about 3 mm width) deprived of the plexus myentericus, was excised and placed in oxygenated Krebs solution containing 10 μ M indomethacin. The

- 19 -

sample is mounted on steel hooks and connected with an isotonic transducer (charge 5 mN). After 90 minutes equilibration a cumulative curve for the agonist ([Sar⁹]Substance P sulphone) was determined. After two or more reproducible curves for the agonist had been obtained, the compound to be tested was added to the bath and a new curve for the agonist was determined in its presence. pA₂ values were calculated by using the constrained Schild plot method.

The data in Table I were obtained for compounds of general formula (I).

Table I


Antagonism of Substance P

Compound of Ex. 1


100% inhibition at 1 μ M

- 20 -

SCHEME 1




SCHEME 2



- 22 -

Claims


- 1 1. Tachykinins antagonist of general formula (I)



2 wherein:

3 Y is chosen in the group consisting of aryl-, aryl-alkyl-, alkyl-aryl-
 4 radical containing from 7 to 12 carbon atoms possibly substituted in the
 5 ring with at least one atom chosen in the group consisting of N, S and O
 6 and possibly substituted on the ring with one or more substituents
 7 independently chosen from halogen, alkyl-radical containing from 1 to 6
 8 carbon atoms possibly substituted with no more than three fluorine atoms.
 9 oxyalkyl-radical containing from 1 to 6 carbon atoms, possibly
 10 substituted with no more than three fluorine atoms. -NH₂. -NHR₁₀. -OR₁₀.
 11 -N(R₁₀)₂. -CONHR₁₀. -COR₁₀. -COOR₁₀. -R₁₀COOR₁₁. -OR₁₀COOR₁₁. -R₁₀COR₁₁.
 12 -CONHR₁₀. -R₁₀CONHR₁₁. -NHCOR₁₀. nitro-radicals wherein R₁₀ and R₁₁ are
 13 hydrogen or an alkyl-radical, linear or branched, containing from 1 to 6
 14 carbon atoms.

15 or Y is a radical of formula:



- 23 -

16 wherein D = O, S, CH₂ and N-R₄ wherein R₄ is chosen in the group
17 constituted by hydrogen, an alkyl-radical, linear or branched, containing
18 from 1 to 6 carbon atoms, an acyl-radical R₉-CO, wherein R₉ is hydrogen
19 or an alkyl-chain containing from 1 to 3 carbon atoms, and wherein E = CH
20 or N, anyone of which can bear suitable substituents;

21 X₁ and X₂, same or different from each other, are chosen in the group
22 consisting of -CONR₈, -NR₈CO-, -CH₂NR₈-, -SO₂NR₈-, wherein R₈ is chosen
23 in the group consisting of hydrogen or an alkyl-chain, linear or
24 modified, containing from 1 to 6 carbon atoms;

25 X₃ is chosen in the group consisting of -CONR₇, -NR₇CO-, -CH₂NR₇-, -
26 SO₂NR₇-, -CN₄-, wherein -CN₄- is a tetrazoline ring and R₇ is chosen in
27 the group consisting of alkyl-, aryl-, aryl-alkyl- or alkyl-aryl-radical
28 with no more than 15 carbon atoms possibly substituted in the ring with
29 at least an atom chosen in the group consisting of N, S and O, possibly
30 substituted on the ring with one or more substituents independently from
31 each other chosen from halogen, alkyl-radical containing from 1 to 6
32 carbon atoms, possibly substituted with no more than three fluorine
33 atoms, oxyalkyl-radical containing from 1 to 6 carbon atoms, possibly
34 substituted with no more than three fluorine atoms, -NH₂, -NHR₁₀, -OR₁₀,
35 -N(R₁₀)₂, -CONHR₁₀, -COR₁₀, -COOR₁₀, -R₁₀COOR₁₁, -OR₁₀COOR₁₁, -R₁₀COR₁₁,
36 -CONHR₁₀, -R₁₀CONHR₁₁, -NHCOR₁₀, nitro-radicals, wherein R₁₀ and R₁₁ are
37 hydrogen or an alkyl-radical, linear or branched, containing from 1 to 6
38 carbon atoms;


39 R₁, R₂ and R₃ independently from each other are hydrogen, halogen, OR₁₂
40 wherein R₁₂ is chosen in the group consisting of hydrogen,

41 -CH₂O(CH₂)₂OCH₃ or -CH₂O(CH₂)₂OCH₂CH₃, or are linked two by two to form

- 24 -

42 an epoxide; A and B can be N, S, O or CH; n is a number from 0 to 2;
 43 R_5 and R_6 are chosen, independently from each other, in the group
 44 consisting of hydrogen, alkyl-, aryl-, aryl-alkyl or alkyl-aryl-radical
 45 containing no more than 15 carbon atoms, possibly substituted in the ring
 46 with at least an atom chosen in the group of N, S and O, possibly
 47 substituted on the ring with one or more substituents chosen
 48 independently from each other from halogen, alkyl-radical containing from
 49 1 to 6 carbon atoms, possibly substituted with no more than three
 50 fluorine atoms, oxyalkyl-radical containing from 1 to 6 carbon atoms,
 51 possibly substituted with no more than three fluorine atoms, an $-NH_2$,
 52 $-NHR_{11}$, $-OR_{10}$, $-N(R_{10})_2$, $-CONHR_{10}$, $-COR_{10}$, $-COOR_{10}$, $-R_{10}COOR_{11}$,
 53 $-OR_{10}COOR_{11}$, $-R_{10}COR_{11}$, $-CONHR_{10}$, $-R_{10}CONHR_{11}$, $-NHCOR_{10}$, nitro-radicals,
 54 wherein R_{10} and R_{11} are hydrogen or an alkyl-radical, linear or branched,
 55 containing from 1 to 6 carbon atoms.


1 2. Compound according to claim 1, wherein:



2 wherein $X_1 = -CONH-$, $X_2 = -CONH-$ and $X_3 = -CONCH_3-$ and wherein R_1 , R_2 ,
 3 R_3 , R_4 , R_5 , R_6 , R_7 , R_9 , R_{10} , R_{11} , A and B are as above defined.

1 3. Compound according to claim 2, wherein:

- 25 -



2 wherein $X_1 = -\text{CONH}-$, $X_2 = -\text{CONH}-$ and $X_3 = -\text{CONCH}_3-$, $R_5 = 2$ -
 3 methylnaphthyl and $R_6 = \text{benzyl}$.

1 4. Compound according to claim 1 wherein the alkyl-radical is preferably
 2 chosen in the group of: methyl, ethyl, propyl, butyl and pentyl; the
 3 alkenyl-radical is chosen between propenyl and butenyl; the aryl-, alkyl-
 4 aryl and aryl-alkyl-radical preferably presents an alkyl-radical as above
 5 defined while the aryl moiety is preferably pyridine, pyrrole,
 6 benzofuran, biphenyl, benzene, indole, naphthalene, tetrahydroquinoline,
 7 imidazole, tetrahydroindoline, quinoline, thienyl, furan, thiofene,
 8 indan, possibly substituted as above defined; cycloalkyl-radical possibly
 9 substituted with at least an atom chosen in the group of N, S and O is
 10 preferably selected in the group of cyclohexane, cyclopentane,
 11 cyclooctane, piperidine, morpholine, piperazine and pyrazine. The term
 12 halogen is chlorine, fluorine, bromine and iodine.

1 5. Compound of general formula (I) according to claim 1 as herein
 2 defined:

3 i) 1-N-[N(1(H)indol-3-yl-carbonyl)-1-amino-cyclohexanecarbonyl]-amino-1-
 4 [N(methyl)N(2-phenylacetyl)]amino-2-phenylethane

5 ii) 1-[N(1(H)indol-3-yl-carbonyl)-1-amino-cyclohexanecarbonyl]-amino-1[N-
 6 (2-phenylacetyl)amino]-2-(2-naphthyl)ethane

7 iii) 1-N-[N(benzoyl)-1-amino-cyclohexanecarbonyl]-amino-1-[N(methyl)N(2-

- 26 -

- 8 phenylacetyl)]amino-2(2-naphthyl)ethane
- 9 iv) 1-N-[N(4-methyl-benzoyl)-1-amino-cyclohexanecarbonyl]-amino-1-
- 10 [N(methyl)N(2-phenylacetyl)]amino-2(2-naphthyl)ethane
- 11 v) 1-N-[N(4-methoxy-benzoyl)-1-amino-cyclohexanecarbonyl]-amino-1-
- 12 [N(methyl)N(2-phenylacetyl)]amino-2(2-naphthyl)ethane
- 13 vi) 1-N-[N(4-chloro-benzoyl)-1-amino-cyclohexanecarbonyl]-amino-1-
- 14 [N(methyl)N(2-phenylacetyl)]amino-2(2-naphthyl)ethane
- 15 vii) 1-N-[N(3,4-chloro-benzoyl)-1-amino-cyclohexanecarbonyl]-amino-1-
- 16 [N(methyl)N(2-phenylacetyl)]amino-2(2-naphthyl)ethane
- 17 viii) 1-N-[N(1(methyl)indol-3-yl-carbonyl)-1-amino-cyclohexanecarbonyl]-
- 18 amino-1-[N(methyl)N(2-phenylacetyl)]amino-2(2-naphthyl)ethane
- 19 ix) 1-N-[N(1(H)indol-3-yl-methyl)-1-amino-cyclohexanecarbonyl]-amino-1-
- 20 [N(methyl)N(2-phenylacetyl)]amino-2(2-naphthyl)ethane
- 21 x) 1-N-[N(1(methyl)indol-3-yl-carbonyl)-N-methyl-1-amino-
- 22 cyclohexanecarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]amino-2(2-
- 23 naphthyl)ethane
- 24 xi) 1-N-[N(1(H)indol-3-yl-carbonyl)-1-amino-cyclohexanecarbonyl]-
- 25 amino-1-[N(methyl)N(2-phenylacetyl)]amino-2(p-methoxy)phenylethane
- 26 xii) N-[N(1(methyl)indol-3-yl-carbonyl)-N-methyl-1-amino-
- 27 cyclohexanecarbonyl]-2 naphthylalanine-N-methyl-N-benzylamide
- 28 xiii) N-[N(1(methyl)indol-3-yl-carbonyl)-N-methyl-1-amino-
- 29 cyclohexanecarbonyl]-2 naphthylalanine-N-methyl-N-benzylamide
- 30 xiv) 1-N-[N(1(H)indol-3-yl-carbonyl)-1-amino-cis-4-hydroxy-
- 31 cyclohexanecarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]-amino-2-
- 32 phenylethane
- 33 xv) 1-[N-(1(H)indol-3-yl-carbonyl)-1-amino-trans-4-hydroxy-

- 27 -

- 34 cyclohexancarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]-amino-2-
35 (2-naphthyl)ethane
- 36 xvi) 1-N-[N(1(H)indol-3-yl-carbonyl)-1-amino-cis-4-methoxyethoxymethoxyl-
37 cyclohexancarbonyl]-amino-1-[N(methyl)N(2-phenylacetyl)]-amino-2-
38 phenylethane
- 39 xvii) 1-[N(1(H)indol-3-yl-carbonyl)-1-amino-trans-4-
40 methoxyethoxymethoxyl-cyclohexancarbonyl]-amino-1-[N(methyl)N(2-
41 phenylacetyl)]-2(2-naphthyl)ethane
- 42 xviii) N-[N(1(H)indol-3-yl-carbonyl)-1-amino-cis-4-hydroxy-
43 cyclohexancarbonyl]-2-naphthylalanine-N-methyl-N-benzylamide
- 44 xix) N-[N(1(H)indol-3-yl-carbonyl)-1-amino-trans-4-hydroxy-
45 cyclohexancarbonyl]-2-naphthylalanine-N-methyl-N-benzylamide
- 46 xx) N-[N(1(H)indol-3-yl-carbonyl)-1-amino-cis-4-methoxyethoxymethoxyl-
47 cyclohexancarbonyl]-phenylalanine-N-methyl-N-benzylamide
- 48 xxi) N-[N(1(H)indol-3-yl-carbonyl)-1-amino-trans-4-
49 methoxyethoxymethoxyl-cyclohexancarbonyl]-phenylalanine-N-methyl-N-
50 benzylamide
- 51 xxii) 1-[N(1(H)indol-3-yl-carbonyl)-1-amino-4-dimethoxy-
52 cyclohexancarbonyl]-amino-1-[N(methyl)-N(2-phenylacetyl)]-amino-2-
53 (2-naphthyl)ethane
- 54 xxiii) N-[N(1(H)indol-3-yl-carbonyl)-1-amino-4-dimethoxy-
55 cyclohexancarbonyl]-2-naphthylalanine-N-methyl-N-benzylamide
- 56 xxiv) 1-[N(1(H)indol-3-yl-carbonyl)-1-amino-4-di(methoxyethoxyethoxy)-
57 cyclohexancarbonyl]-amino-1-[N(methyl)-N(2-phenylacetyl)]-amino-2-(2-
58 naphthyl)ethane
- 59 xxv) N-[N(1(H)indol-3-yl-carbonyl)-1-amino-4-di(methoxyethoxymethoxy)-

- 28 -

60 cyclohexanecarbonyl]-2-naphthylalanine-N-methyl-N-benzylamide
61 xxvi) 1-[N(1(H)indol-3-yl-carbonyl)-4-amino-tetrahydropyranyl-4-
62 carbonyl]-amino-1[N(methyl)-N(2-phenylacetyl)]-amino-2-(2-naphthyl)ethane
63 xxvii) N-[N(1(H)indol-3-yl-carbonyl)-4-amino-tetrahydropyranyl-4-
64 carbonyl]-2-naphthylalanine-N-methyl-N-benzylamide
65 xxviii) 1-[N(1(H)indol-3-yl-carbonyl)-4-amino-piperidin-4-carbonyl]-
66 amino-1[N(methyl)-N(2-phenylacetyl)]-amino-2-(2-naphthyl)ethane
67 xxix) N-[N(1(H)indol-3-yl-carbonyl)-4-amino-piperidin-4-carbonyl]-2-
68 naphthylalanine-N-methyl-N-benzylamide
69 xxx) 1-[N(1(H)indol-3-yl-carbonyl)-4-amino-1-dimethyl-piperidin-4-
70 carbonyl]-amino-1-[N(methyl)-N(2-phenylacetyl)]-amino-2-(2-
71 naphthyl)ethane
72 xxxi) N-[N(1(H)indol-3-yl-carbonyl)-4-amino-1-dimethylpiperidin-4-
73 carbonyl]-2-naphthylalanine-N-methyl-N-benzylamide.

1 6. Pharmaceutical composition comprising as active principle a
2 therapeutically effective amount of compound of formula (I) according to
3 claim 1.

1 7. Pharmaceutical composition comprising as active principle a
2 therapeutically effective amount of compound of formula (I) according to
3 claim 2.


1 8. Pharmaceutical composition comprising as active principle a
2 therapeutically effective amount of compound of formula (I) according to
3 claim 3.

1 9. Use of compounds of formula (I) according to claims 1, 2, 3, 4 as
2 active principle for the preparation of pharmaceutical compositions.


1 10. Process for the preparation of compounds of general formula (I):

- 29 -

2 wherein:



3 Y is chosen in the group consisting of aryl-, aryl-alkyl-, alkyl-aryl-
 4 radical containing from 7 to 12 carbon atoms possibly substituted in the
 5 ring with at least one atom chosen in the group consisting of N, S and O
 6 and possibly substituted on the ring with one or more substituents
 7 independently chosen from halogen, alkyl-radical containing from 1 to 6
 8 carbon atoms possibly substituted with no more than three fluorine atoms,
 9 oxyalkyl-radical containing from 1 to 6 carbon atoms, possibly
 10 substituted with no more than three fluorine atoms, $-NH_2$, $-NHR_{10}$, $-OR_{10}$,
 11 $-N(R_{10})_2$, $-CONHR_{10}$, $-COR_{10}$, $-COOR_{10}$, $-R_{10}COOR_{11}$, $-OR_{10}COOR_{11}$, $-R_{10}COR_{11}$,
 12 $-CONHR_{10}$, $-R_{10}CONHR_{11}$, $-NHCOR_{10}$, nitro-radicals wherein R_{10} and R_{11} are
 13 hydrogen or an alkyl-radical, linear or branched, containing from 1 to 6
 14 carbon atoms.
 15 or Y is a radical of formula:



- 30 -

16 wherein D = O, S, CH₂ and N-R₄ wherein R₄ is chosen in the group
17 constituted by hydrogen, an alkyl-radical, linear or branched, containing
18 from 1 to 6 carbon atoms, an acyl-radical R₉-CO, wherein R₉ is hydrogen
19 or an alkyl-chain containing from 1 to 3 carbon atoms, and wherein E = CH
20 or N, anyone of which can bear suitable substituents;

21 X₁ and X₂, same or different from each other, are chosen in the group
22 consisting of -CONR₈, -NR₈CO-, -CH₂NR₈-, -SO₂NR₈-, wherein R₈ is chosen
23 in the group consisting of hydrogen or an alkyl-chain, linear or
24 modified, containing from 1 to 6 carbon atoms;

25 X₃ is chosen in the group consisting of -CONR₇, -NR₇CO-, -CH₂NR₇-, -
26 SO₂NR₇-, -CN₄-, wherein -CN₄- is a tetrazoline ring and R₇ is chosen in
27 the group consisting of alkyl-, aryl-, aryl-alkyl- or alkyl-aryl-radical
28 with no more than 15 carbon atoms possibly substituted in the ring with
29 at least an atom chosen in the group consisting of N, S and O, possibly
30 substituted on the ring with one or more substituents independently from
31 each other chosen from halogen, alkyl-radical containing from 1 to 6
32 carbon atoms, possibly substituted with no more than three fluorine
33 atoms, oxyalkyl-radical containing from 1 to 6 carbon atoms, possibly
34 substituted with no more than three fluorine atoms, -NH₂, -NHR₁₀, -OR₁₀,
35 -N(R₁₀)₂, -CONHR₁₀, -COR₁₀, -COOR₁₀, -R₁₀COOR₁₁, -OR₁₀COOR₁₁, -R₁₀COR₁₁,
36 -CONHR₁₀, -R₁₀CONHR₁₁, -NHCOR₁₀, nitro-radicals, wherein R₁₀ and R₁₁ are
37 hydrogen or an alkyl-radical, linear or branched, containing from 1 to 6
38 carbon atoms;


39 R₁, R₂ and R₃ independently from each other are hydrogen, halogen, OR₁₂
40 wherein R₁₂ is chosen in the group consisting of hydrogen,
41 -CH₂O(CH₂)₂OCH₃ or -CH₂O(CH₂)₂OCH₂CH₃, or are linked two by two to form

- 31 -


42 an epoxide; A and B can be N, S, O or CH; n is a number from 0 to 2;
 43 R_5 and R_6 are chosen, independently from each other, in the group
 44 consisting of hydrogen, alkyl-, aryl-, aryl-alkyl or alkyl-aryl-radical
 45 containing no more than 15 carbon atoms, possibly substituted in the ring
 46 with at least an atom chosen in the group of N, S and O, possibly
 47 substituted on the ring with one or more substituents chosen
 48 independently from each other from halogen, alkyl-radical containing from
 49 1 to 6 carbon atoms, possibly substituted with no more than three
 50 fluorine atoms, oxyalkyl-radical containing from 1 to 6 carbon atoms,
 51 possibly substituted with no more than three fluorine atoms, an $-NH_2$,
 52 $-NHR_{11}$, $-OR_{10}$, $-N(R_{10})_2$, $-CONHR_{10}$, $-COR_{10}$, $-COOR_{10}$, $-R_{10}COOR_{11}$,
 53 $-OR_{10}COOR_{11}$, $-R_{10}COR_{11}$, $-CONHR_{10}$, $-R_{10}CONHR_{11}$, $-NHCOR_{10}$, nitro-radicals,
 54 wherein R_{10} and R_{11} are hydrogen or an alkyl-radical, linear or
 55 branched, containing from 1 to 6 carbon atoms;

56 according to the following steps:

57 a) preparation of the intermediate of formula (II):



58 and of the intermediate of formula (III) wherein X_5 is NH_2 when X_4 is
 59 $COOH$ while X_5 is $COOH$ when X_4 is NH_2 :



- 32 -


60 and R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{12} , A, B, Y, X_1 , X_2 , X_3 ,
 61 are as above defined in claim 1;

62 b) condensation, in the presence of a suitable condensing agent of the
 63 two above said intermediates;


64 c) isolation and purification of the product from step (b) by
 65 chromatography.

1 11. Process for the preparation of a compound of formula (I) according to
 2 claim 10 by sequential condensation on the intermediate of general
 3 formula (III), as above described wherein X_5 is NH_2 , of the two residues
 4 of general formula (XI) and (XII)

Y-COOH
 (XII)



1 12. Compound of general formula (II)




2 wherein R_1 , R_2 , R_3 , R_5 , R_6 , A, B, X_1 , X_2 , X_3 , X_4 , X_5 are as defined in

- 33 -

3 claim 1.

1 13. compound of general formula (III)


(III)



1 wherein $R_1, R_2, R_3, R_5, R_6, A, B, X_1, X_2, X_3, X_4, X_5$ are as defined in
 2 claim 1.

1 14. Compound of general formula (XI)

(XI)



2 wherein $R_1, R_2, R_3, R_5, R_6, A, B, X_1, X_2, X_3, X_4, X_5$ are as defined in
 3 claim 1.

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/EP 95/00193

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D209/42 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 443 132 (FUJISAWA PHARMACEUTICAL CO.,LTD.) 28 August 1991 see claims ---	1,6
A	EP,A,0 394 989 (FUJISAWA PHARMACEUTICAL CO.,LTD.) 31 October 1990 see claims ---	1,6
A	JOURNAL OF MEDICINAL CHEMISTRY, vol. 36,no. 16, 6 August 1993 pages 2266-2278, DAIJIRO HAGIWARA ET AL. 'Studies on neurokinin antagonists. 3....' * page 2267 * ---	1,6
P,A	WO,A,94 13694 (A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L.) 23 June 1994 see claims -----	1,6

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

3 May 1995

Date of mailing of the international search report

19.05.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 95/00193

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-443132	28-08-91	AU-B- 640185	19-08-93
		AU-A- 6801090	27-06-91
		CN-A- 1064080	02-09-92
		DE-D- 69005286	27-01-94
		DE-T- 69005286	21-04-94
		ES-T- 2060910	01-12-94
		FI-B- 93548	13-01-95
		JP-A- 4210996	03-08-92
EP-A-394989	31-10-90	AT-T- 115961	15-01-95
		DE-D- 69015244	02-02-95
		JP-A- 3027399	05-02-91
		US-A- 5164372	17-11-92
WO-A-9413694	23-06-94	AU-B- 5650894	04-07-94

Form PCT/ISA/210 (patent family annex) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 95/00193

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
CLAIMS SEARCHED INCOMPLETELY : 1 - 4
CLAIMS NOT SEARCHED : 12-14
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/EP95/00193

FURTHER INFORMATION CONTINUED FROM PCT/ISA/

The vast number of theoretically conceivable compounds resulting from the general formula (I) with its broadly defined substituents precludes a comprehensive search. In accordance with the single example and guided by the concept of the invention as inferred from the list of compounds what can be drained, the search was limited to the general formula (I) wherein :

Y = 3-indolyl or a possibly substituted phenyle

B = CH

A = CH, O or N

X1= -CONR8-

X2= -CONR8-

n = 1

Concerning the intermediates (claims 12-14)- of which claim 13 can hardly be searched at all-these have not been searched "per se" because of the novelty of the end-products and for reasons of economy of the search. (cf. Arts. 6, 15 and rule 33 PCT ; see guidelines B-III 2.1)

